The FDA has approved Rybelsus® to reduce the risk of MACE in adults with T2DM who are at high risk for these events.

Bispecific antibody treatments remain a promising treatment for diabetic macular edema (DME), as a new study shows that faricimab was effective and had durable results after a year of real-world ...

In 2026, updates are coming to Medicare Part D. This will have a real impact, as it is estimated that 81% of Medicare recipients are using the Part D plan ...